Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 114

  • 1 388 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 388 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 388 clinical trials

Relapsing multiple sclerosis

Not recruiting
Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Diroximel Fumarate
  • Sponsor:Biogen Idec Research Limited

Dementia Alzheimer's type

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Biogen Idec Research Limited

Magnetic resonance imaging+1

Not recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Isodicentric chromosome 15 syndrome+3

Not recruiting
InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Soticlestat
  • Sponsor:Takeda Development Center Americas Inc.

Giant cell arteritis

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Status epilepticus

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Craniocerebral injury

Not recruiting
Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Parkinson's disease

Not recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Suvecaltamide
  • Sponsor:Cavion Inc.

Angelman's syndrome

Not recruiting
InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Rugonersen
  • Sponsor:F. Hoffmann-La Roche AG

Secondary progressive multiple sclerosis

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Intervertebral disc protrusion+2

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gabapentin
  • Sponsor:Groupement Des Hopitaux De L'Institut Catholique De Lille

Dementia Alzheimer's type

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lecanemab
  • Sponsor:Washington University School Of Medicine

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.